Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
February 10, 2026 - 03:34
Praxis Precision Medicines, Inc., a leader in central nervous system precision neuroscience, has scheduled the release of its fourth quarter and full year 2025 financial results for Thursday, February 19, 2026. The announcement will be made public prior to the opening of the financial markets that day.
Following the release, the company's management will host a conference call and live webcast to discuss the financial performance and provide a comprehensive corporate update. This event will offer investors and analysts direct insight into the company's recent progress and strategic outlook.
In addition to the earnings report, Praxis has confirmed its participation in several upcoming investor conferences. These engagements are part of the company's ongoing commitment to maintaining transparent communication with the investment community and sharing developments in its pipeline of precision neuroscience therapies. The company focuses on developing treatments for psychiatric and neurological disorders by targeting genetic drivers of brain disease.
MORE NEWS
May 11, 2026 - 10:36
How Improved Q1 Results and New API Partnership Could Shape Lincoln National’s (LNC) Investment StoryLincoln National Corporation reported first-quarter 2026 results earlier this month, posting revenue of $5.31 billion. The company recorded a net loss of $172 million, an improvement from the...
May 10, 2026 - 20:14
A Florida Salesperson Thought He Was Helping People Go Solar. Now He Complains To Dave Ramsey He's Really Selling Loans, Not Solar PanelsA Florida man who thought he was joining the solar industry to help people save money and the environment says he quickly discovered the real job was selling loans, not panels. He brought his...
May 10, 2026 - 04:02
AMETEK Bets $5 Billion on Indicor Deal to Boost Industrial Tech PortfolioAMETEK has announced a definitive agreement to buy the Instrumentation group of businesses from Indicor, LLC for $5 billion in cash. The company`s management called the acquisition a highly...
May 9, 2026 - 04:47
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For ShareholdersDamora Therapeutics has announced a significant shake-up in its executive ranks, appointing Jennifer Jarrett as the new President and CEO. In a parallel move, the company named Brian Burkavage as...